157 related articles for article (PubMed ID: 16075919)
21. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
22. Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: a possible autoantigenic link in Graves' patients.
Kromminga A; Hagel C; Arndt R; Schuppert F
J Clin Endocrinol Metab; 1998 Aug; 83(8):2817-23. PubMed ID: 9709953
[TBL] [Abstract][Full Text] [Related]
23. Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy.
Salvi M; Bingoye F; Chung F; Wall JR
J Clin Endocrinol Metab; 1988 May; 66(5):939-45. PubMed ID: 3360902
[TBL] [Abstract][Full Text] [Related]
24. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease.
Bahn RS
J Clin Endocrinol Metab; 2003 May; 88(5):1939-46. PubMed ID: 12727937
[No Abstract] [Full Text] [Related]
25. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay.
Ahmann A; Baker JR; Weetman AP; Wartofsky L; Nutman TB; Burman KD
J Clin Endocrinol Metab; 1987 Mar; 64(3):454-60. PubMed ID: 2434519
[TBL] [Abstract][Full Text] [Related]
26. Thyroid-associated eye disease: pathophysiology.
Weetman AP
Lancet; 1991 Jul; 338(8758):25-8. PubMed ID: 1676091
[No Abstract] [Full Text] [Related]
27. Current evidence for and against the TSH receptor being the common antigen in Graves' disease and thyroid associated ophthalmopathy.
Paschke R; Vassart G; Ludgate M
Clin Endocrinol (Oxf); 1995 Jun; 42(6):565-9. PubMed ID: 7634495
[No Abstract] [Full Text] [Related]
28. Eyeing up Graves' ophthalmopathy.
Weetman AP
Mol Cell Endocrinol; 1997 Feb; 126(2):113-6. PubMed ID: 9089648
[No Abstract] [Full Text] [Related]
29. Tear film profile in Graves' ophthalmopathy.
Khurana AK; Sunder S; Ahluwalia BK; Malhotra KC
Acta Ophthalmol (Copenh); 1992 Jun; 70(3):346-9. PubMed ID: 1636395
[TBL] [Abstract][Full Text] [Related]
30. Definition, at the molecular level, of a thyroglobulin-acetylcholinesterase shared epitope: study of its pathophysiological significance in patients with Graves' ophthalmopathy.
Ludgate M; Dong Q; Dreyfus PA; Zakut H; Taylor P; Vassart G; Soreq H
Autoimmunity; 1989; 3(3):167-76. PubMed ID: 2485081
[TBL] [Abstract][Full Text] [Related]
31. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
[TBL] [Abstract][Full Text] [Related]
32. Graves' ophthalmopathy and the TSH receptor.
Franklyn JA
Lancet; 1993 Aug; 342(8867):318-9. PubMed ID: 8101579
[No Abstract] [Full Text] [Related]
33. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
[TBL] [Abstract][Full Text] [Related]
34. Regional assignment of the gene coding for a human Graves' disease autoantigen to 10q21.3-q22.1.
Rossi E; Zarrilli R; Zuffardi O
Hum Genet; 1993 Feb; 90(6):653-4. PubMed ID: 8444471
[TBL] [Abstract][Full Text] [Related]
35. Motility disturbances in Graves' ophthalmopathy.
de Waard R; Koornneef L; Verbeeten B
Doc Ophthalmol; 1983 Dec; 56(1-2):41-7. PubMed ID: 6689301
[TBL] [Abstract][Full Text] [Related]
36. Graves' ophthalmopathy: a preventable disease?
Bartalena L; Marcocci C; Pinchera A
Eur J Endocrinol; 2002 Apr; 146(4):457-61. PubMed ID: 11916611
[TBL] [Abstract][Full Text] [Related]
37. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
[TBL] [Abstract][Full Text] [Related]
38. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
39. Similarity and dissimilarity between clinical and laboratory findings, especially anti-thyrotropin receptor antibody in ophthalmic Graves' disease without persistent hyperthyroidism and hyperthyroid Graves' disease.
Kosugi S; Inoue D; Sugawa H; Enomoto T; Mori T; Imura H
Endocrinol Jpn; 1990 Jun; 37(3):343-54. PubMed ID: 2253584
[TBL] [Abstract][Full Text] [Related]
40. [Current understanding of pathogenesis of Graves ophthalmopathy].
Ando T; Eguchi K
Nihon Rinsho; 2006 Dec; 64(12):2275-8. PubMed ID: 17154091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
